Table 3.

Statistics of univariate analyses of clinicopathological parameters, Immunogradient and intratumoral immune cell density indicators for patient overall survival.

Clinicopathological Parameters, Immunogradient and Intratumoral Cell Density Indicators	CRC, n = 87
	HR	95% CI	p-Value *
Age group (>median vs. ≤median)	1.33	0.64–2.77	0.4480
Sex (male vs. female)	0.84	0.40–1.77	0.6481
TNM stage (III-IV vs. I-II)	1.06	0.49–2.30	0.8825
pT status (pT4 vs. pT2-3)	1.05	0.45–2.46	0.9151
pN status (pN1-2 vs. pN0)	0.98	0.45–2.18	0.9683
M status (M1 vs. M0)	3.41	0.80–14.60	0.0978
G stage (G3 vs. G2)	1.60	0.74–3.46	0.2312
LVI status (LVI1 vs. LVI0)	1.77	0.56–2.43	0.6737
Pne status (Pne1 vs. Pne0)	1.67	0.68–4.12	0.2648
Tumor location (right/transverse/multiple vs. left)	2.00	0.85–4.68	0.1128
Tumor growth pattern (infiltrative vs. pushing margin)	2.81	1.32–5.98	0.0075 *
Tumor budding (high vs. low)	2.05	0.98–4.29	0.0556
Peritumoral lymphocytes (inconspicuous vs. conspicuous)	1.28	0.61–2.69	0.5234
MSI status (MSI vs. MSS)	2.07	0.97–4.43	0.0614
BRAF status (mutant vs. wild-type)	0.98	0.44–2.18	0.9501
KRAS status (mutant vs. wild-type)	0.78	0.36–1.72	0.5369
PIK3CA status (mutant vs. wild-type)	0.59	0.21–1.70	0.3264
CD8_CM (high vs. low)	0.31	0.15–0.66	0.0013 *
CD8_d_S (high vs. low)	1.46	0.64–3.31	0.3600
CD8_d_TE (high vs. low)	0.64	0.31–1.35	0.2400
CD8_d_T (high vs. low)	0.53	0.25–1.10	0.0850
INT_CD8 (high vs. low)	2.13	0.93–4.88	0.0670
CD20_CM (high vs. low)	0.39	0.16–0.91	0.0230 *
CD20_d_S (high vs. low)	0.30	0.12–0.75	0.0061 *
CD20_d_TE (high vs. low)	0.33	0.10–1.08	0.0530
CD20_d_T (high vs. low)	0.43	0.20–0.90	0.0210 *
INT_CD20 (high vs. low)	0.41	0.18–0.90	0.0230 *
CD68_CM (high vs. low)	1.77	0.84–3.74	0.1300
CD68_d_S (high vs. low)	0.59	0.28–1.23	0.1500
CD68_d_TE (high vs. low)	0.65	0.30–1.43	0.2800
CD68_d_T (high vs. low)	1.82	0.77–4.26	0.1600
INT_CD68 (high vs. low)	1.73	0.79–3.81	0.1700

HR hazard ratio, CI confidence interval. * p-value < 0.05 is considered significant.